Physician profile
Marshall E Belaga
NPI 1568492478
$4,644.21
in general payments reported to CMS, 2019-2025
23 companies · $976 in 2025
The $976 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $532 · 2021: $944 · 2022: $618 · 2023: $952 · 2024: $287 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $715.01 | 2019-2025 | Spravato, Invega Trinza |
| Alkermes, INC. | $658.37 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $598.66 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $389.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $376.99 | 2019-2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $312.57 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.11 | 2021-2025 | Caplyta |
| Abbvie INC. | $252.81 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $237.45 | 2019-2024 | Ingrezza |
| Livanova USA, INC. | $129.60 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Avadel Cns Pharmaceuticals, LLC | $124.26 | 2025 | Lumryz |
| Lundbeck LLC | $94.83 | 2020-2025 | Abilify Asimtufii |
| W. L. Gore & Associates, INC. | $84.92 | 2019 | |
| Allergan, INC. | $70.34 | 2019-2021 | |
| Indivior INC. | $57.83 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.39 | 2020-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $49.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.78 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $34.46 | 2019 | |
| Corium, LLC | $22.90 | 2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $20.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.21 | 2025 | |
| Eisai INC. | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Belaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.